Form 4: SpringWorks Therapeutics General Counsel Disposes of Equity Following Merger with Merck KGaA

Herschel S. Weinstein, General Counsel and Secretary of SpringWorks Therapeutics, Inc., disposed of all his beneficial ownership in the company's equity and derivative securities effective July 1, 2025, as a result of the company's merger with Merck KGaA.

Summary

• SpringWorks Therapeutics, Inc. completed its merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, with SpringWorks becoming a wholly-owned subsidiary of Merck KGaA.
• Herschel S. Weinstein, General Counsel and Secretary of SpringWorks Therapeutics, disposed of all his direct beneficial ownership in the company's common stock and derivative securities on July 1, 2025.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash per share.
• The disposal included 55,239 shares of common stock, which incorporated 32,906 shares underlying restricted stock units (RSUs).
• Performance Share Units (PSUs) totaling 15,157 were also disposed of, converting into cash-based awards.
• Stock options with exercise prices below the $47.00 merger consideration were converted into cash-based awards, while options with exercise prices greater than $47.00 were cancelled for no consideration.
• Specific stock options disposed of included 106,600 at an exercise price of $33.70, 125,000 at $27.64, 60,000 at $38.40, and 35,431 at $43.00.
• Unvested RSUs and stock options were converted into Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards, respectively, which will generally vest according to their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing, subject to continued employment.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a completed merger, which is generally a positive event for shareholders receiving cash consideration. It is a factual report of a transaction rather than a performance update, indicating a neutral to slightly positive sentiment for the former shareholders.

Positives

• The merger provided a clear cash exit for SpringWorks Therapeutics shareholders at a fixed price of $47.00 per share.
• Unvested equity awards held by employees, including the reporting person, were converted into cash-based awards, ensuring continued value and providing retention incentives post-merger.

Negatives

• SpringWorks Therapeutics ceased to be an independent publicly traded company.
• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no consideration, resulting in a loss of potential value for holders of those options.

Risks

• The risk of stock options being out-of-the-money was realized for options with an exercise price above $47.00, leading to their cancellation without payment.

Future Outlook

SpringWorks Therapeutics is now a wholly-owned subsidiary of Merck KGaA. Unvested equity awards held by employees, including the reporting person, have been converted into cash-based awards that will continue to vest, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing, subject to the applicable holder's continued employment with Parent.

Management Comments

• The filing details the actions taken by Herschel S. Weinstein, General Counsel & Secretary, in response to the merger, indicating his compliance with the terms of the Merger Agreement regarding the disposition of his equity holdings.

Industry Context

This Form 4 filing reflects the finalization of a significant corporate acquisition within the biotechnology and pharmaceutical sector. Such mergers are common as larger pharmaceutical companies like Merck KGaA seek to expand their pipelines and capabilities by acquiring smaller, innovative biotech firms like SpringWorks Therapeutics. This transaction represents a strategic consolidation within the industry.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Received $47.00 in cash per share, providing a liquidity event and a defined return on their investment.
• Employees (including the reporting person): Unvested equity awards were converted into cash-based awards, providing continued financial incentives and promoting retention within the new parent company structure.
• Company (SpringWorks Therapeutics): Transitioned from an independent public entity to a wholly-owned subsidiary, impacting its operational autonomy and strategic direction, which will now be aligned with Merck KGaA.

Next Steps

• Integration of SpringWorks Therapeutics into Merck KGaA's operations.
• Continued vesting and payment of cash-based equity awards for eligible employees over the specified vesting periods.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, SEC Form 4, Insider Transaction, Equity Disposal, Restricted Stock Units, Performance Share Units, Stock Options, Corporate Action, Biotechnology, Pharmaceuticals